These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21450541)

  • 1. Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.
    Cummings J; Zhou C; Dive C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(13-14):887-93. PubMed ID: 21450541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
    Linder S; Olofsson MH; Herrmann R; Ulukaya E
    Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
    Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
    Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
    Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
    Cummings J; Ranson M; Butt F; Moore D; Dive C
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):921-4. PubMed ID: 17333190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Cummings J; Ranson M; Lacasse E; Ganganagari JR; St-Jean M; Jayson G; Durkin J; Dive C
    Br J Cancer; 2006 Jul; 95(1):42-8. PubMed ID: 16804528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
    de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
    Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
    Cummings J; Hodgkinson C; Odedra R; Sini P; Heaton SP; Mundt KE; Ward TH; Wilkinson RW; Growcott J; Hughes A; Dive C
    Mol Cancer Ther; 2008 Mar; 7(3):455-63. PubMed ID: 18347133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serum M30 and M65 levels in patients with breast cancer.
    Tas F; Karabulut S; Yildiz I; Duranyildiz D
    Biomed Pharmacother; 2014 Oct; 68(8):1135-40. PubMed ID: 25465151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimisation of circulating biomarkers of cell death for routine clinical use.
    Greystoke A; Cummings J; Ward T; Simpson K; Renehan A; Butt F; Moore D; Gietema J; Blackhall F; Ranson M; Hughes A; Dive C
    Ann Oncol; 2008 May; 19(5):990-5. PubMed ID: 18304966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum M65 as a biomarker for metastatic renal cell carcinoma.
    Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
    Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum M30 and M65 levels in melanoma.
    Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
    Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
    Ausch C; Buxhofer-Ausch V; Olszewski U; Hinterberger W; Ogris E; Schiessel R; Hamilton G
    Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker method validation in anticancer drug development.
    Cummings J; Ward TH; Greystoke A; Ranson M; Dive C
    Br J Pharmacol; 2008 Feb; 153(4):646-56. PubMed ID: 17876307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokeratin 18 as a biomarker for gastric cancer.
    Oyama K; Fushida S; Kinoshita J; Okamoto K; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
    Clin Exp Med; 2013 Nov; 13(4):289-95. PubMed ID: 22825587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma.
    Sen F; Yildiz I; Odabas H; Tambas M; Kilic L; Karadeniz A; Altun M; Ekenel M; Serilmez M; Duranyildiz D; Bavbek S; Basaran M
    Tumour Biol; 2015 Feb; 36(2):1039-44. PubMed ID: 25326440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum profiles of M30, M65 and interleukin-17 compared with C-reactive protein in patients with mild and severe acute pancreatitis.
    Vlachos S; Tsaroucha AK; Konstantoudakis G; Papachristou F; Trypsianis G; Schizas D; Vaos G; Simopoulos C
    J Hepatobiliary Pancreat Sci; 2014 Dec; 21(12):911-8. PubMed ID: 25214429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum levels of cell death circulating biomarkers, M30 and M65, in patients with β-thalassemia major.
    Esmaeil N; Moayedi B; Gharagozloo M; Maracy MR
    Hemoglobin; 2013; 37(4):404-10. PubMed ID: 23600495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.
    Tas F; Karabulut S; Bilgin E; Sen F; Yildiz I; Tastekin D; Ciftci R; Duranyildiz D
    Tumour Biol; 2013 Dec; 34(6):3529-36. PubMed ID: 23784459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Death and Prognosis of Mortality in Alcoholic Hepatitis Patients Using Plasma Keratin-18.
    Woolbright BL; Bridges BW; Dunn W; Olson JC; Weinman SA; Jaeschke H
    Gene Expr; 2017 Nov; 17(4):301-312. PubMed ID: 28770701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.